Bisphosphonates and tetracycline: Experimental models for their evaluation in calcium-related disorders

Pharmaceutical Research

Volumn 15, Issue 4, 1998, Pages 606-613

  Cohen, Hagit ^a   Solomon, Vered ^a   Alferiev, Ivan S ^a   Breuer, Eli ^a   Ornoy, Asher ^a   Patlas, Natan ^a   Eidelman, Naomi ^b   Hägele, Gerhard ^c   Golomb, Gershon ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY   (United States)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Bisphosphonates; Bone resorption; Calcification; Hydroxyapatite; Synthesis; Tetracycline

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; TETRACYCLINE;

ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CALCIFICATION; CALCIUM METABOLISM; CATION EXCHANGE; DRUG ACTIVITY; DRUG SCREENING; DRUG SYNTHESIS; ELECTROLYTE DISTURBANCE; EXPERIMENTAL MODEL; HYPERCALCEMIA; OSTEOLYSIS; PAGET BONE DISEASE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ALENDRONATE; ANIMALS; ANTI-INFLAMMATORY AGENTS; BETAINE; BONE AND BONES; BONE RESORPTION; CALCINOSIS; CHELATING AGENTS; DIPHOSPHONATES; EDETIC ACID; HINDLIMB; HYDROXYAPATITES; MALE; PROTEIN SYNTHESIS INHIBITORS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TETRACYCLINE;

EID: 0031925310     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011990129437     Document Type: Article

References (42)

1. O. L. M. Bijvoet, H. A. Fleisch, R. E. Canfield, and R. G. G. Russell. Bisphosphonates on bones, Elsevier Science B.V., Amsterdam, 1995.
2. H. Fleisch. Bisphosphonates: A new class of drugs in diseases of bone and calcium metabolism. In K. W. Brunner, H. Fleisch, and H.-J. Senn (eds.), Bisphosphonates and tumor osteolysis, Springer-Verlag, Berlin Heidelberg, 1989, pp. 1-29.
3. J. M. Van Gelder, E. Breuer, A. Ornoy, A. Schlossman, N. Patlas, and G. Golomb. Anticalcification and antiresorption effects of bisacylphosphonates. Bone 16:511-520 (1995).
4. J. M. Van Gelder and G. Golomb. The evaluation of bisphosphonates as potential drugs for the treatment of calcium-related disorders. In A. Ornoy (eds.). Animal models of human related calcium metabolic disorders, CRC, Boca Raton, 1995, pp. 181-205.
5. U. A. Liberman, et al. Effect of oral alendronate on bone mineral density and incidence of fractures in postmenopausal osteoporosis. N. Eng. J. Med. 333:1437-1443 (1995).
6. H. A. Fleisch. Bisphosphonates: Preclinical aspects and use in osteoporosis. Annals Medicine 29(1):55-62. (1997).
7. W. Jeal, L. B. Barradell, and D. McTavish. Alendronate: A review of its pharmacological properties and therapeutic efficacy in post-menopausal osteoporosis. Drugs 53(3):415-434. (1997).
8. H. Fleisch. Bisphosphonates: Mechanism of action and clinical use. In G. R. Mundy, and T. J. Martin (eds.), Physiology and pharmacology of bone, Springer-Verlag, Heidelberg, 1993.
9. M. Sahni, H. L. Guenther, H. Fleisch, P. Collin, and T. J. Martin. Biphosphonates act on rat bone resorption through the mediation of osteoblasts. J. Clin. Invest. 91:2004-2011 (1993).
10. G. A. Rodan and R. Balena. Bisphosphonates in the treatment of metabolic bone diseases. Ann. Med. 25:373-378 (1993).
11. G. Golomb, A. Schlossman, H. Saadeh, M. Levi, J. M. Van Gelder, and E. Breuer. Bisacylphosphonates inhibit hydroxyapatite formation and dissolution in vitro and dystrophic calcification in vivo. Pharm. Res. 9:143-148 (1992).
12. G. Golomb, A. Schlossman, Y. Eitan, H. Saadeh, J. M. Van Gelder, and E. Breuer. In vitro and in vivo anticalcification effects of novel bishydroxyiminophosphonates. J. Pharm. Sci. 81:1004-1007 (1992).
13. E. Van Beek, M. Hoekstra, M. Van de Ruit, C. W. G. M. Lowik, and S. E. Papapoulos. Structural requirements for bisphosphonate actions in vitro. J. Bone Miner. Res. 9:1875-1882 (1994).
14. M. J. Rogers, D. J. Watts, R. G. G. Russell, X. Ji, X. Xiong, G. M. Blackburn, A. V. Bayless, and F. H. Ebetino. Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold dictyostelium discoideum. J. Bone Miner. Res. 9:1029-1039 (1994).
15. A. D. Geddes, S. M. D'Souza, F. H. Ebetino, and K. J. Ibbotson. Bisphosphonates: Structure-activity relationships and therapeutic implications. In J. N. M. Heersche, and J. A. Kanis (eds.), Bone and Mineral Research, Elsevier, Amsterdam, 1994, pp. 265-306.
16. W. K. Sietsema, F. H. Ebetino, A. M. Salvagno, and J. A. Bevan. Antiresorptive dose-response relationships across three generations of bisphosphonates. Drugs Exptl. Clin. Res. XV:389-396 (1989).
17. J. R. Green, K. Muller, and K. A. Jaeggi. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J. Bone Miner. Res. 9:745-751 (1994).
18. I. S. Alferiev, I. L. Kotlyarevski, N. V. Mikhalin, and V. M. Novikova. Reactions of vinylidenebisphosphonic acid with nucleophiles. Comm. 1. Addition of aliphatic amines. Bull. Nat. Acad. USSR Ser. Chem. 2802-2806 (1983).
19. J. H. Lin, I.-W. Chen, and F. A. Deluna. On the absorption of alendronate in rats. J. Pharm. Sci. 83:1741-1746 (1994).
20. J. H. Lin. Bisphosphonates: a review of their pharmacokinetic properties. Bone 18: 75-85 (1996).
21. G. R. Kieczkowski, R. B. Jobson, D. G. Melillo, D. F. Reinhold, V. J. Grenda, and I. Shinkai. Preparation of (4-Amino-1-Hydroxybutylidene) bisphosphonic acid sodium salt, MK-217 (alendronate sodium). An improved procedure for the preparation of 1-hydroxy-1,1-bisphosphonic acids. J. Org. Chem. 60:8310-8312 (1995).
22. G. Golomb and D. Wagner. Development of a new in vitro model for studying implantable polyurethane calcification. Biomaterials 12:397-405 (1991).
23. 3 on long bones of glucocorticoid treated mice. Acta Anat. 145:61-67 (1992).
24. 3H] tetracycline kinetics andd indices of kidney function facilitate study of the activity and toxic effects of bisphosphonates in bone resorption. Pharm. Res. 9:1018-1023 (1992).
25. D.D. Perrin. Dissociation constants of organic bases in aqueous solution, Butterworths, London, 1965.
26. M. Sato and W. Grasser. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J. Bone Miner. Res. 5:31-40 (1991).
27. D. E. Hughes, M. Mian, D. F. Guilland-Cumming, and R. G. G. Russell. The cellular mechanism of action of bisphosphonates. Drugs Exptl. Clin. Res. XVII: 109-114 (1991).
28. S. J. Sunberg, F. H. Ebetino, C. T. Mosher, and C. F. Root. Designing drugs for stronger bones. Chemtech 21:304-309 (1991).
29. D. J. Rowe and L. A. Etre. Uptake of a fluorinated bisphosphonate by cultured bones. Bone 9:297-301 (1988).
30. T. Fonong, D. J. Burton, and D. J. Pietrzyk. Determination of formation constants of calcium complexes of difluoromethylene-diphosphonic acid and related diphosphonates. Anal. Chem. 55:1089-1094 (1983).
31. F. H. Ebetino and L. A. Jamieson. The design and synthesis of bone-active phosphinic acid analogues: I. The pyridylaminomethane phosphonoalkylphosphinates. Phosphorus Sulfur Silicon 51:23-26 (1990).
32. Remington. The science and practice of pharmacy, Mack Publishing Company, Pennsylvania, 1995.
33. M. L. Lamson, J. M. Fox, and W. I. Higuchi. Calcium and 1-hydroxyethylidene-1,1-bisphosphonic acid: Polynuclear complex formation in the physiological range of pH. Int. J. Pharm. 21:143-154 (1984).
34. D. Hirsch, F. J. Schoen, and R. J. Levy. Effects of metallic ions and diphosphonates on inhibition of pericardial bioprosthetic tissue calcification and associated alkaline phosphatase activity. Biomaterials 14:371-377 (1993).
35. M. D. Francis and R. R. Martodam. Chemical, biochemical, and medicinal properties of the diphosphonates. In R. L. Hilderbrand (eds.), The role of phosphonates in living systems, CRC Press, Boca Raton, 1983, pp. 55-96.
36. R. Schenk, W. A. Merz, R. Muhlbauer, R. G. G. Russell, and H. Fleisch. Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (CIMDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and methaphysis of rats. Calcif. Tiss. Res. 11:196-214 (1973).
37. P. H. Reitsma, O. L. M. Bijvoet, H. Verlinden-Ooms, and L. J. A. van der Wee-Pals. Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats. Calcif. Tiss. Int. 32:145-157 (1980).
38. B. Adamson, S. Gallacher, J. Byars, S. Ralston, I. Boyle, and B. Boyce. Mineralization defects with pamidronate therapy for Paget's disease. Lancet 342:1459-1460 (1993).
39. S. Q. Cohlan and T. Tiamsic. Growth inhibition of prematures receiving tetracycline. Am. J. Dis. Child. 105:65-73 (1963).
40. S. Williams, A. Wakisaka, Q. Q. Zeng, J. Barnes, G. Martin, W. J. Wechter, and C. T. Liang. Minocycline prevents the decrease in bone mineral density and trabecular bone in ovariectomized aged rats. Bone 19:637-644 (1996).
41. 3H] tetracycline. J. Pharm. Sci. 78:823-828 (1989).
42. M. I. Kabachnik, T. Y. Medreved', N. M. Dyaglova, Y. M. Policarpov, B. K. Scherbakov, and F. I. Bel'skii. Synthesis and acid-base and complexing properties of amino-substituted α-hydroxyalkylidenediphosphonic acids. Bull. Nat. Acad. USSR Ser. Chem. 374-377 (1978).